Publicaciones en las que colabora con Joan Montaner Villalonga (20)

2024

  1. Statistical analysis plan for the multicenter, open, randomized controlled clinical trial to assess the efficacy and safety of intravenous tirofiban vs aspirin in acute ischemic stroke due to tandem lesion, undergoing recanalization therapy by endovascular treatment (ATILA trial)

    Trials, Vol. 25, Núm. 1

2023

  1. Safety and Efficacy of ApTOLL in Patients with Ischemic Stroke Undergoing Endovascular Treatment: A Phase 1/2 Randomized Clinical Trial

    JAMA Neurology, Vol. 80, Núm. 8, pp. 779-788

  2. Safety and efficacy of tirofiban in acute ischemic stroke due to tandem lesions undergoing mechanical thrombectomy: A multicenter randomized clinical trial (ATILA) protocol

    European Stroke Journal, Vol. 8, Núm. 1, pp. 380-386

  3. The current situation of Telestroke in Spain

    Neurologia

2022

  1. Proprotein convertase subtilisin/kexin type 9 inhibitors in secondary prevention of vascular events in patients with stroke: Consensus document and practice guidance

    Neurologia, Vol. 37, Núm. 2, pp. 136-150

2021

  1. Rp11-362k2.2:Rp11-767i20.1 genetic variation is associated with post-reperfusion therapy parenchymal hematoma. a gwas meta-analysis

    Journal of Clinical Medicine, Vol. 10, Núm. 14

  2. Single nucleotide variations in ZBTB46 are associated with post-thrombolytic parenchymal haematoma

    Brain, Vol. 144, Núm. 8, pp. 2416-2426

2020

  1. Blood biomarkers predictive of epilepsy after an acute stroke event

    Epilepsia, Vol. 61, Núm. 10, pp. 2244-2253

  2. Correlation of blood biomarkers with early-onset seizures after an acute stroke event

    Epilepsy and Behavior, Vol. 104

  3. Corrigendum to “Correlation of blood biomarkers with early-onset seizures after an acute stroke event” [Epilepsy Behav 104(Pt B) (2020 Mar)] (Epilepsy & Behavior (2020) 104(PB), (S1525505019305219), (10.1016/j.yebeh.2019.106549))

    Epilepsy and Behavior

2019

  1. PATJ Low Frequency Variants Are Associated with Worse Ischemic Stroke Functional Outcome: A Genome-Wide Meta-Analysis

    Circulation Research, Vol. 124, Núm. 1, pp. 114-120

2017

  1. Blood Biomarkers for the Early Diagnosis of Stroke: The Stroke-Chip Study

    Stroke, Vol. 48, Núm. 9, pp. 2419-2425

  2. GRECOS Project (Genotyping Recurrence Risk of Stroke): The Use of Genetics to Predict the Vascular Recurrence after Stroke

    Stroke, Vol. 48, Núm. 5, pp. 1147-1153

2016

  1. Changes in Activated Thrombin-Activatable Fibrinolysis Inhibitor Levels Following Thrombolytic Therapy in Ischemic Stroke Patients Correlate with Clinical Outcome

    Cerebrovascular Diseases, Vol. 42, Núm. 5-6, pp. 404-414

2014

  1. Prognostic value of blood interleukin-6 in the prediction of functional outcome after stroke: A systematic review and meta-analysis

    Journal of Neuroimmunology, Vol. 274, Núm. 1-2, pp. 215-224

2012

  1. A predictive clinical-genetic model of tissue plasminogen activator response in acute ischemic stroke

    Annals of Neurology, Vol. 72, Núm. 5, pp. 716-729

  2. Role of the MMP9 gene in hemorrhagic transformations after tissue-type plasminogen activator treatment in stroke patients

    Stroke, Vol. 43, Núm. 5, pp. 1398-1400

2006

  1. Pretreatment hemostatic markers of symptomatic intracerebral hemorrhage in patients treated with tissue plasminogen activator

    Stroke, Vol. 37, Núm. 4, pp. 996-999

2005

  1. Hemostatic markers of recanalization in patients with ischemic stroke treated with rt-PA

    Neurology, Vol. 65, Núm. 3, pp. 366-370

  2. Molecular Signatures of Course and Prognosis of Intracerebral Hemorrhage

    Seminars in Cerebrovascular Diseases and Stroke, Vol. 5, Núm. 3, pp. 178-188